Literature DB >> 19801969

Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms.

Yi-Hua Chen1, Juehua Gao, Guang Fan, LoAnn C Peterson.   

Abstract

Sox11 is a transcription factor involved in embryonic neurogenesis and tissue remodeling. Its role in lymphopoiesis is presently unknown. Recent studies have shown the nuclear expression of sox11 in mantle cell lymphoma, which raises the question about its possible association with t(11;14)(q13;q32), the genetic hallmark of mantle cell lymphoma leading to the overexpression of cyclin D1. In this study, we examined sox11 expression in 211 cases of B-cell neoplasms by immunohistochemistry, and evaluated its association with t(11;14) and overexpression of cyclin D1. Nuclear staining of sox11 was observed in 54 of 57 (95%) mantle cell lymphomas, including 52 of 53 (98%) classical and 2 of 4 variant types. Two of the three mantle cell lymphomas negative for nuclear sox11 staining were analyzed and were positive for t(11;14). All other B-cell lymphomas (114 cases) showed variable positive staining in the cytoplasm, but no nuclear positivity. Sox11 was then examined in plasma cell myeloma and hairy cell leukemia as a subset of plasma cell myeloma carry t(11;14) and overexpress cyclin D1, and cyclin D1 is overexpressed in a subset of hairy cell leukemia independent of t(11;14). We found no nuclear staining of sox11 in 30 plasma cell myelomas examined, including 12 cases with t(11;14)(q13;q32). It is interesting that intense nuclear staining of sox11 was present in a subset of hairy cell leukemias (5 of 10), and was associated with the overexpression of cyclin D1. Our results indicate that the nuclear expression of sox11 is highly associated with mantle cell lymphoma, but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Its association with the overexpression of cyclin D1 in hairy cell leukemia suggests that sox11 may be involved in the upregulation of cyclin D1 in this leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801969     DOI: 10.1038/modpathol.2009.140

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.

Authors:  P-Y Kuo; V V Leshchenko; M J Fazzari; D Perumal; T Gellen; T He; J Iqbal; S Baumgartner-Wennerholm; L Nygren; F Zhang; W Zhang; K S Suh; A Goy; D T Yang; W-C Chan; B S Kahl; A K Verma; R D Gascoyne; E Kimby; B Sander; B H Ye; A M Melnick; S Parekh
Journal:  Oncogene       Date:  2014-03-31       Impact factor: 9.867

2.  Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden.

Authors:  Falko Fend; José Cabecadas; Philippe Gaulard; Elaine S Jaffe; Philip Kluin; Isinsu Kuzu; Loann Peterson; Andrew Wotherspoon; Christer Sundström
Journal:  J Hematop       Date:  2012-09       Impact factor: 0.196

3.  CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

Authors:  David Martín-Garcia; Alba Navarro; Rafael Valdés-Mas; Guillem Clot; Jesús Gutiérrez-Abril; Miriam Prieto; Inmaculada Ribera-Cortada; Renata Woroniecka; Grzegorz Rymkiewicz; Susanne Bens; Laurence de Leval; Andreas Rosenwald; Judith A Ferry; Eric D Hsi; Kai Fu; Jan Delabie; Dennis Weisenburger; Daphne de Jong; Fina Climent; Sheila J O'Connor; Steven H Swerdlow; David Torrents; Sergi Beltran; Blanca Espinet; Blanca González-Farré; Luis Veloza; Dolors Costa; Estella Matutes; Reiner Siebert; German Ott; Leticia Quintanilla-Martinez; Elaine S Jaffe; Carlos López-Otín; Itziar Salaverria; Xose S Puente; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2018-12-11       Impact factor: 22.113

4.  Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.

Authors:  Paolo Conrotto; Ulrika Andréasson; Venera Kuci; Carl A K Borrebaeck; Sara Ek
Journal:  Mol Oncol       Date:  2011-08-22       Impact factor: 6.603

5.  The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases.

Authors:  Xin Cao; Lei Fan; Cheng Fang; Dan-Xia Zhu; Hua-Jie Dong; Dong-Mei Wang; Yin-Hua Wang; Wei Xu; Jian-Yong Li
Journal:  Med Oncol       Date:  2011-04-09       Impact factor: 3.064

6.  Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression.

Authors:  Joel F Gradowski; Rachel L Sargent; Fiona E Craig; Kathleen Cieply; Kim Fuhrer; Carol Sherer; Steven H Swerdlow
Journal:  Am J Clin Pathol       Date:  2012-07       Impact factor: 2.493

7.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to November 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-12-17       Impact factor: 0.196

8.  SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies.

Authors:  Elin Gustavsson; Sandra Sernbo; Elin Andersson; Donal J Brennan; Michael Dictor; Mats Jerkeman; Carl Ak Borrebaeck; Sara Ek
Journal:  Mol Cancer       Date:  2010-07-12       Impact factor: 27.401

9.  Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.

Authors:  Inmaculada Ribera-Cortada; Daniel Martinez; Virginia Amador; Cristina Royo; Alba Navarro; Silvia Beà; Eva Gine; Laurence de Leval; Sergio Serrano; Andrew Wotherspoon; Dolors Colomer; Antonio Martinez; Elías Campo
Journal:  Mod Pathol       Date:  2015-09-11       Impact factor: 7.842

10.  SOX11 augments BCR signaling to drive MCL-like tumor development.

Authors:  Pei-Yu Kuo; Shashidhar S Jatiani; Adeeb H Rahman; Donna Edwards; Zewei Jiang; Katya Ahr; Deepak Perumal; Violetta V Leshchenko; Joshua Brody; Rita Shaknovich; B Hilda Ye; Samir Parekh
Journal:  Blood       Date:  2018-04-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.